Skip to main content
Delfa

← Trials/Trial dossier/NCT00602680

TerminatedPhase 2

Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease

A Multicenter, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance and Safety/Tolerability of SSR180711C for 4 Weeks, Using Donepezil as Calibrator, in Patients With Mild Alzheimer's Disease

Lead sponsor

Sanofi

Assets

Donepezil / SSR180711C

Listed sites

1

Recruiting sites

-

Enrollment

1

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoint

•Cognitive performance

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

SecondaryEudraCT 2007-001639-80
NCT IDNCT00602680
Org study IDPDY10400
SecondarySSR180711

Timeline

Milestones

Study start2008-01 (month precision)
Study first posted2008-01-28estimated
Primary completion2008-07actual (month precision)
Study completion2008-07actual (month precision)
Last update posted2009-07-20estimated

Assets

Drug assets

DonepezilSSR180711C

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years
Maximum age90 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Outpatients with diagnosis of mild AD

Exclusion criteria

•Concomitant or previous treatment by acetylcholinesterase inhibitors and/or memantine
•Medical condition which may interfere with the study
•History of epileptic seizures
•Lens opacity
•Lack of reliable caregiver

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition
1
Other (unclassified)
1

Global cognition

1 endpoint
Primary/protocol endpoint

Change in cognitive performance

Time frame:4 weeks

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Cognitive, global, functional and behaviorial assessments

Time frame:4 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.